Biodexa Pharmaceuticals Azioni (NASDAQ: BDRX)

Ultime notizie per Biodexa Pharmaceuticals (NASDAQ:BDRX) Azioni

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals PLC

BOMBARDIER 6.25% PFD A by Bombardier Inc.

Bombardier Inc

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/20085852/Unisound-0620-900x600-1.png" alt="" class="wp-image-14657" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/20085852/Unisound-0620-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/20085852/Unisound-0620-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/20085852/Unisound-0620-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The AI services provider is aiming to raise a relatively modest $40 million, or just over 2% of its share capital, as it rapidly burns through its cash
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Unisound aims to raise about $40 million through a Hong Kong IPO, with its shares set to start trading on June 30</li>
<li>The AI services provider recorded 29% revenue growth last year and has a relatively diverse customer base, but is rapidly burning through its cash</li>
</ul>
Is the market for new AI listings becoming oversaturated?
That question was front-and-center in the latest&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0620/2025062000023.pdf">listing document</a>&nbsp;from&nbsp;Unisound AI Technology Co. Ltd.&nbsp;(9678.HK), which launched its Hong Kong IPO on Friday with a very modest fundraising target of up to HK$320 million ($41 million). The company plans to sell 1.56 million shares in the listing, representing just 2.2% of its share capital, which seems to show it's not extremely confident of big demand for the stock.
What's more, Unisound said it has already found cornerstone investors to buy about one-third of the shares on offer, meaning it's aiming to sell around just 1 million shares to other investors for between HK$165 and HK$205 apiece. A pricing at the top of its range would give the company a market value of HK$14.5 billion, though it seems more likely it could price closer to the bottom, which would value it at $11.7 billion, according to the latest listing document.
The stock is set to make its trading debut on June 30.
So, why is Unisound so hesitant with this offering? The company provides AI products and services designed to help healthcare and more general clients from sectors like hospitality and transportation, run their operations more efficiently. It's growing at a respectable, though not eye-popping, rate, including 29% revenue growth last year.
But the company is cash-flow negative, and consumed over half of its cash last year. It's also making its listing into one of Hong Kong's strongest IPO markets in years, which means sentiment is positive, but also that investors have lots of other choices – including a growing number of other AI companies that have listed or are moving in that direction. While most of the AI companies are losing money and are also cash-flow negative, many have larger cash reserves.
Unisound's cash reserves tumbled to just 156 million yuan by the end of last year, down by more than half from 379 million yuan at the end of 2023, as the company reported 319 million yuan in cash outflow during the year, according to&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107247/documents/sehk25033000666.pdf">its prospectus</a>&nbsp;first filed in March. Its IPO will provide some relief by providing roughly another 275 million yuan in new cash. But that's still not too much, considering its current rate of cash burn.
"We believe that we possess sufficient working capital, including sufficient cash and liquidity assets, to meet our present needs and for the next 12 months from the date of the document," the company said in its listing document, reflecting its tenuous situation. Of course, it's quite likely Unisound will sell more shares to raise additional cash through secondary offerings, especially if the initial offering gets a positive reception. But that's far from guaranteed.
Despite the cautionary signs, Unisound is still aiming for a relatively high valuation compared with its peers. Its price-to-sales (P/S) ratio would range from 11 to 14, depending on how its shares price. But even a pricing at the low end of that range would be equal to the P/S ratio of 11.5 for&nbsp;SenseTime&nbsp;(0200.HK), and is well ahead of the 3.82 for&nbsp;Fourth Paradigm&nbsp;(6682.HK), two other AI companies that are both much larger.
<h4 class="wp-block-heading">Solid financials</h4>
Despite its precarious position, Unisound's financials look relatively decent, and it also seems quite disciplined in terms of cost controls. The company is an old-timer on China's AI scene, with a history dating back to 2012 when its predecessor was set up by Liang Jia'en and Kang Heng, who both have scientific backgrounds. It began working on its core Atlas AI infrastructure, which underpins its current products, in 2016. The company counts the well-respected Qiming as one of its investors, with more than 6% of its shares.
Unisound divides its business into two main segments. The larger of the two is its general "life" segment, which accounts for more than 80% of its revenue and includes customers from the residential and commercial property sectors, as well as hospitality and transportation. Its customers include the likes of the Shenzhen Metro system, which used Unisound's services to create a voice ticketing system for one of its lines.
The other segment is healthcare, which helps companies do things like record medical records, manage their insurance payments and conduct quality control functions more efficiently. That segment accounted for about 15% of the company's revenue last year, though it was growing more quickly than the "life" segment.
From a customer perspective, Unisound looks quite sound with a relatively diverse customer base, showing its products have relatively broad appeal. That's something you don't always see in the emerging AI services sector, where companies are often reliant on just a handful of customers for a big chunk of their revenue. By comparison, Unisound's five largest customers accounted for just 26.7% of its revenue last year, down from 30.8% in 2022.
The company's overall revenue grew 29% last year to 939 million yuan from 727 million yuan in 2023. Its gross margin looked relatively healthy last year at 38.8%, though we should note that was quite a bit lower than SenseTime and Fourth Paradigm, whose gross margins for the year were both around 48%.
Unisound's biggest expense is R&amp;D, which is quite common in the fast-developing AI space. But even there, its R&amp;D spending growth rate of 29% last year was in line with its revenue growth, showing the company is trying to take a disciplined spending approach. Its sales and marketing expenses grew by a slower 20%, and its administrative costs actually fell slightly last year. As a result, its overall operating expenses rose just 21%, quite a bit slower than its overall revenue growth.
Despite that discipline, the company's adjusted net loss still widened by 22% last year to 168 million yuan from 137 million yuan in 2023.
At the end of the day, Unisound looks like a relatively sound company, with good growth prospects, a diverse customer base and disciplined spending. Now, it just needs to find a way to keep funding its operations until it can become profitable, which appears to be at least another three to four years away.

Asia

IPOs

Opinion

Unisound Launches Modest IPO In Crowded Hong Kong Market

Home Depot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) is looking to acquire GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>), a Georgia-based building products distributing company.
as per The Wall Street Journal's report. 
What Happened: This move from Depot can commence a bidding war in the fragmented construction material space with Brad Jacob's QXO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>), according to <a href="https://www.wsj.com/business/deals/home-depot-bid-kicks-off-a-battle-for-5-billion-building-products-company-05cf2060">a</a> report by The Wall Street Journal.
QXO on June 19 hit the headlines with its unsolicited offer of $5 billion, a $95.20 per share all-cash offer to acquire GMS with a response deadline of June 24. Now, Home Depot's similar desire with undisclosed financial terms has positioned it directly against QXO.
GMS, a prominent North American building material distributor, operates with more than 320 distribution centers and around 100 tool rental locations across the U.S. and Canada.
The pressured profitability due to the deflation in prices of steel and high operating costs has drawn takeover interest from players in the overlapping sector.
SEE ALSO: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45966388/gms-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">GMS Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Why It Matters: Signals of Brad Jacob's interest in acquiring soared the prices of GMS, which lately had modest sales growth of approximately 3%. While QXO, launched in December 2023, is smaller compared to Home Depot in terms of capitalization, it is known for its M&amp;A expertise under Jacob's leadership.
The continued aggressive push by the retailers signals an expansion of the professional contractor market, the segment that has already been enlarging into multibillion-dollar acquisitions, such as the purchase of SRS Distribution, a Texas-based distributor, by Home Depot for $18.25 billion.
As per the report, QXO's bid is being evaluated by the GMS's board. If they fail to respond by the end of the deadline, QXO will escalate its offer directly to the shareholders.
Read Next
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Hhttps://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-falas Fallen.">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen.</a></li>
</ul>
Photo: Shutterstock

Equities

Home Depot Eyes GMS Acquisition, Setting Stage For Bidding War With QXO

As of June 20, 2025, two stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to &lt;a href=&#8221;https://pro.benzinga.com/&#8221;> Benzinga Pro&lt;/a>.  
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Arqit Quantum Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>)</h3>
<ul class="wp-block-list">
<li>On May 27, Arqit Quantum announced it will acquire Ampliphae&#8217;s technology IP. &#8220;Encryption Intelligence is a vital choice for organisations looking to understand and reduce their encryption risk,&#8221; said Andy Leaver, CEO of Arqit. &#8220;By combining our quantum encryption expertise with Ampliphae&#8217;s analytics technologies, we can deliver unmatched protection and advisory services on a global scale.&#8221; The company's stock jumped around 54% over the past month and has a <a href="https://www.benzinga.com/quote/ARQQ">52-week high of $52.79</a>.</li>
<li>RSI Value: 82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ARQQ Price Action: Shares of Arqit Quantum gained 22.4% to close at $37.97 on Wednesday.</li>
<li>Edge Stock Ratings: 98.21 Momentum score with Value at 0.64. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/arqq"><img loading="lazy" decoding="async" width="422" height="175" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20052307/image-306.png" alt="" class="wp-image-955763" style="width:316px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20052307/image-306.png 422w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20052307/image-306-300x124.png 300w" sizes="(max-width: 422px) 100vw, 422px" /></a></figure>
<h3 class="wp-block-heading">Silicon Motion Technology Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>)</h3>
<ul class="wp-block-list">
<li>On June 17, Roth Capital analyst Suji Desilva maintained Silicon Motion Technology with a Buy and raised the price target from $70 to $90. The company's stock gained around 10% over the past month and <a href="https://www.benzinga.com/quote/SIMO">has a 52-week high</a> of $85.87.</li>
<li>RSI Value: 78.4</li>
<li>SIMO Price Action: Shares of Silicon Motion Technology gained 4.5% to close at $71.49 on Wednesday.</li>
</ul>
Don't miss out on the full BZ Edge Rankings—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">compare all the key stocks now</a>.
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

Trading Ideas

ARQQ

SIMO

Top 2 Tech Stocks That Could Sink Your Portfolio In June

WIIM

SWBI

Smith & Wesson shares are trading lower after the company reported worse-than-expected Q4 EPS and sales.

GRRR

Gorilla Technology Group shares are trading higher after the company reported a year-over-year increase in revenue.

OpenAI chief executive Sam Altman says he "didn't think Elon was going to abuse his power in the government to unfairly compete" but now believes he was wrong after Tesla's founder allegedly tried to derail OpenAI's $500 billion "Stargate" data-center deal.
What Happened: Altman made the remarks on the first <a href="https://www.youtube.com/watch?v=DB9mjd-65gw&amp;t=1s">episode</a> of the OpenAI Podcast, adding, "I regret to say I was wrong about that … I'm grateful the administration did the right thing and stood up to his behaviour." The Wall Street Journal reported last month that <a href="https://www.benzinga.com/25/05/45688477/elon-musk-pressured-trump-team-to-include-his-xai-in-the-openaioracle-abu-dhabi-deal-threatening-to-block-it-otherwise-report">Musk lobbied officials</a> to block the project unless it included his own startup, xAI.
Stargate aims to build the world's largest cluster of AI data centers outside the United States, with a first gigawatt-scale site in Abilene, Texas, slated to go online in 2026. SoftBank will finance the multi-phase complex, Son Masayoshi will chair it and OpenAI will operate the facilities. Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) and MGX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) have taken minority stakes.
Hours after the podcast dropped, Musk posted on X, "Scam Altman strikes again." He has <a href="https://www.benzinga.com/tech/24/12/42257564/musk-goes-to-court-to-block-openais-for-profit-transition">repeatedly accused</a> OpenAI, which he co-founded as a nonprofit in 2015, of becoming "a closed-source de-facto subsidiary" of Microsoft and sued the lab for allegedly abandoning its original mission.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Scam Altman strikes again
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1935539112746041422?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See also: <a href="https://www.benzinga.com/markets/asia/25/06/46022846/elon-musks-tesla-to-build-first-grid-scale-energy-storage-site-in-china-with-550-million-investment">Elon Musk&#8217;s Tesla To Build First Grid-Scale Energy Storage Site In China With $550 Million Investment</a>
Why It Matters: Altman warns that attempts to kneecap rivals will slow domestic capacity and "be unfortunate for the country," but predicted Stargate will proceed &#8220;at the speed we want.&#8221;
Meanwhile, OpenAI&#8217;s relationship with Microsoft has not been at its best lately. OpenAI is weighing <a href="https://www.benzinga.com/markets/tech/25/06/45966911/openai-vs-microsoft-inside-the-brewing-power-struggle-that-could-reportedly-explode-into-an-antitrust-showdown">whether to accuse</a> Microsoft of anticompetitive tactics and ask federal regulators to scrutinize their contract, a move that could upend the companies' once-cozy alliance, The Wall Street Journal reported Monday.
Executives want to curb Microsoft's sway over OpenAI's products and computing power, yet they still need Microsoft's approval to convert OpenAI into a fully for-profit business that could raise more capital or go public. The firm's planned <a href="https://www.benzinga.com/personal-finance/entrepreneurship/25/05/45705941/openai-secures-11-6b-for-texas-data-center-expansion-reducing-microsoft-dependence">Texas data-center</a> buildout likewise aims to lessen reliance on Microsoft's cloud resources.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/news/fda/25/06/46023093/fda-approves-gileads-game-changing-twice-yearly-shot-to-prevent-hiv-transmission-critics-slam-28k-price-tag">FDA Approves Gilead&#8217;s &#8216;Game Changing&#8217; Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag</a>

Tech

ORCL

Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe

Caris Life Sciences shares are trading higher amid post-IPO strength.

<a href="https://www.bloomberg.com/news/articles/2025-06-20/tesla-to-open-first-india-stores-in-july-imports-from-china-begin" title="https://www.bloomberg.com/news/articles/2025-06-20/tesla-to-open-first-india-stores-in-july-imports-from-china-begin">https://www.bloomberg.com/news/articles/2025-06-20/tesla-to-open-first-india-stores-in-july-imports-from-china-begin</a>

TSLA

Bloomberg Reports Tesla Will Open India Showrooms In Jul.

CarMax shares are trading higher after the company reported better-than-expected Q1 financial results. Also, the company reported an increase in Q1 retail used unit sales, comparable store used unit sales and wholesale units sales.

GMS shares are trading higher following a report suggesting Home Depot made an offer to acquire the company. QXO reportedly submitted an unsolicited offer to buy the company.

SoftBank Group Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) founder Masayoshi Son is spearheading an alliance with Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), proposing a $1 trillion industrial complex in Arizona.
 Son intends to double down on the robotics and artificial intelligence infrastructure with this project.
What Happened: The proposed mega project aims to position the US as a global hub of robotics and hardware manufacturing, according to <a href="https://www.reuters.com/business/media-telecom/softbanks-son-pitches-1-trillion-us-ai-hub-tsmc-trump-team-bloomberg-news-2025-06-20/">a</a> Bloomberg report.
This project is separate from the Stargate project, a joint venture led by OpenAI, SoftBank, and Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>).
The company&#8217;s latest Arizona plan would go beyond data centers and focus on AI-enabled manufacturing and robotics, expanding its footprint from digital infrastructure to physical AI deployment.
Also Read: <a href="https://www.benzinga.com/media/25/04/44873349/openai-and-softbanks-stargate-considers-major-uk-investment-to-fuel-ai-growth">OpenAI And SoftBank&#8217;s Stargate Considers Major UK Investment To Fuel AI Growth</a>
Why It Matters: Softbank is determined to have the Taiwanese company on board for the project, as per Bloomberg's report.
SoftBank seeks to leverage the Trump administration's interest in developing domestic high-tech manufacturing with federal and state tax incentives to encourage investment in the proposed Arizona industrial complex.
With the tussle between the U.S.–China tech intensifying and the semiconductor supply chain being erratic in the current tariff war, Son's $1 trillion bet could be a game-changer for the US. But convincing the investors and policymakers and the lack of interest indicated by the TSMC, could be a hindrance.   
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45965120/softbank-moves-to-raise-4-9-billion-with-overnight-t-mobile-block-sale-stock-drops-4-after-hours-as-investors-digest-discount">SoftBank Moves To Raise $4.9 Billion With Overnight T-Mobile Block Sale— Stock Drops 4% After Hours As Investors Digest Discount</a></li>
</ul>
Photo: Michael Vi/Shutterstock

SFTBY

SoftBank's Masayoshi Son Proposes $1 Trillion Robotics And AI Hub In Arizona With TSMC

Wedbush analyst Daniel Ives maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Outperform and raises the price target from $300 to $325.

Price Target

Analyst Ratings

Wedbush Maintains Outperform on IBM, Raises Price Target to $325

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/17/final-trades-southern-comfort-uber-the-ieo-and-the-iym.html">Halftime Report Final Trades</a>,&#8221; Stephen Weiss, Chief Investment Officer and Managing Partner of Short Hills Capital Partners, named The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), saying the IPO window opens at this point <a href="https://www.benzinga.com/quote/GS/news">and it should benefit from a major standpoint.</a>
As per recent news, Goldman Sachs Asset Management on Wednesday announced that the Fund&#8217;s Board of Trustees, at the recommendation of GSAM, has approved a plan of liquidation for each Fund.
Kevin Simpson, Capital Wealth Planning founder and CIO, picked NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) as his final trade.
Supporting his view, Barclays analyst Tom O&#8217;Malley maintained Nvidia with an Overweight rating on June 17 and raised the price target from $170 to $200.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Bill Baruch, founder and president of both Blue Line Capital and Blue Line Futures, named MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>), an industrial name. He added that the company's power delivery is up 58% year over year.
Lending support to his choice, Goldman Sachs analyst Ati Modak upgraded MasTec from Neutral to Buy on June 6 and raised the price target from $156 to $195.
Joseph Terranova, senior managing director of Virtus Investment Partners, said JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) is up 35% from its April low.
On the earnings front, JPMorgan will host a conference call on Tuesday, July 15, to review second-quarter financial results.
Price Action:
<ul class="wp-block-list">
<li>Goldman Sachs shares gained 1.7% to close at $635.24 on Wednesday.</li>
<li>Nvidia rose 0.9% to settle at $145.48 during the session.</li>
<li>MasTec shares gained 1.2% to settle at $164.66 during the session.</li>
<li>JPMorgan gained 1.7% to close at $273.96 on Wednesday.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

NVDA

Nvidia, Goldman Sachs, JPMorgan And An Industrial Stock On CNBC's 'Final Trades'

CICC initiates coverage on Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform rating and announces Price Target of $225.

Initiation

SNOW

CICC Initiates Coverage On Snowflake with Outperform Rating, Announces Price Target of $225

Contracts

AMZN

Amazon And SK Group Announces They Will Invest ~$5B To Build South Korea's Largest Data Center

Wedbush analyst Matthew Bryson maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and raises the price target from $130 to $150.

Wedbush Maintains Outperform on Micron Technology, Raises Price Target to $150

Darden Restaurants shares are trading higher after the company reported better-than-expected Q4 financial results.

<h3>Gainers</h3>
<ul>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) shares moved upwards by 17.3% to $6.25 during Friday's pre-market session. The company's market cap stands at $124.9 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock rose 14.7% to $1.17. The market value of their outstanding shares is at $12.3 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) stock increased by 10.39% to $7.17. The market value of their outstanding shares is at $3.5 million. </li>
<li>CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) shares increased by 10.36% to $71.0. The market value of their outstanding shares is at $9.8 billion. The company's, Q1 earnings came out today. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares moved upwards by 10.0% to $9.02. The company's market cap stands at $141.3 million. </li>
<li>Carbon Revolution (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) shares increased by 8.18% to $2.38. The company's market cap stands at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) stock declined by 12.8% to $9.49 during Friday's pre-market session. The company's market cap stands at $478.7 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) stock fell 9.57% to $12.2. The company's market cap stands at $689.5 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock declined by 5.72% to $0.31. The company's market cap stands at $1.8 million. </li>
<li>Wah Fu Education Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) stock declined by 5.31% to $1.32. The company's market cap stands at $6.1 million. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) stock declined by 4.6% to $0.81. The company's market cap stands at $12.3 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) stock fell 4.49% to $0.5. The company's market cap stands at $6.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CREV

EZGO

JFBR

SPHL

WAFU

YSXT

Connexa Sports Technologies Inc. - Common Stock

YYAI

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 19.6% to $3.59 during Friday's pre-market session. The company's market cap stands at $38.5 million. </li>
<li>Quantum BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) stock moved upwards by 18.45% to $35.75. The market value of their outstanding shares is at $87.7 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares moved upwards by 17.97% to $0.29. The market value of their outstanding shares is at $2.8 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock moved upwards by 12.09% to $2.78. The market value of their outstanding shares is at $14.6 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares moved upwards by 11.87% to $35.73. The company's market cap stands at $419.7 million. </li>
<li>Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares increased by 11.79% to $1.99. The market value of their outstanding shares is at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 18.4% to $51.7 during Friday's pre-market session. The market value of their outstanding shares is at $824.3 million. </li>
<li>Terns Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) shares decreased by 16.75% to $3.33. The market value of their outstanding shares is at $349.3 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares declined by 14.24% to $4.4. The company's market cap stands at $3.4 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock declined by 11.66% to $0.25. The market value of their outstanding shares is at $9.4 million. </li>
<li>Insight Molecular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMDX#NASDAQ">IMDX</a>) shares decreased by 11.4% to $2.8. The company's market cap stands at $90.3 million. </li>
<li>Opus Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) shares fell 10.75% to $0.83. The market value of their outstanding shares is at $55.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

APVO

CODX

GLMD

IMDX

PCSA

QNTM

SMLR

TERN

VVOS

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares increased by 79.3% to $0.39 during Friday's pre-market session. The company's market cap stands at $2.0 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) shares moved upwards by 36.22% to $1.13. The market value of their outstanding shares is at $10.3 million. </li>
<li>GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) stock increased by 27.14% to $103.0. The company's market cap stands at $3.0 billion. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock increased by 18.93% to $2.01. The company's market cap stands at $4.7 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) stock moved upwards by 10.26% to $0.75. The company's market cap stands at $53.9 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares rose 10.08% to $2.51. The company's market cap stands at $71.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) stock declined by 11.8% to $1.94 during Friday's pre-market session. The company's market cap stands at $16.5 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) stock decreased by 11.23% to $7.75. The market value of their outstanding shares is at $20.8 million. </li>
<li>SU Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) shares decreased by 9.79% to $0.46. The company's market cap stands at $7.0 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares fell 9.52% to $0.08. The company's market cap stands at $12.2 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) stock declined by 8.03% to $0.41. The market value of their outstanding shares is at $13.1 million. </li>
<li>Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) shares declined by 7.15% to $1.17. The market value of their outstanding shares is at $78.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIYA

DFLI

GPUS

HOVR

LGCL

RBNE

RYDE

SUGP

TYGO

12 Industrials Stocks Moving In Friday's Pre-Market Session

Press Releases

Preliminary Results for the Year Ended 31 December 2024

Notice of General Meeting

Result of General Meeting

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational  eRapa Phase 3 Program in FAP  Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company")  Notice of General Meeting

Shareholder Update

Biodexa Announces Recruitment of First Patient  in Phase 2 Study of Tolimidone in Type 1 Diabetes

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

BDRX

Aditxt

Alzamend Neuro

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Entero Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Oragenics

Onconetix

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Ladenburg Thalmann

Screenshot 2025-06-17 at 8.31.13 PM

Biotech

General

Screenshot 2025-03-18 at 8.36.36 PM

Fast Track Designation Secured, Successful Protocol Discussion With FDA And CROs Confirmed, Biodexa On Track To Initiate Funded Phase 3 FAP Trial Next Quarter

Untitled design - 2025-02-11T232646.924

Following Positive Phase 2 Results And Orphan Drug Designation, Biodexa&#39;s FAP Drug Receives FDA Fast Track Status

Image

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic

Untitled design - 2024-10-16T235234.675

Biodexa&#39;s MX-110 Continues To Show Promise In Recurrent Glioblastoma (rGBM), The Deadliest Brain Cancer

Screenshot 2024-07-10 at 9.15.35 PM

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa In Treatment Of Precancerous Polyps In The GI Tract – Now 12-Month Data

Screenshot 2024-06-03 at 5.21.04 PM

Promising Phase 2 Results For Biodexa&#39;s eRapa™ Indicates Hope For FAP Patients Who Otherwise Have A 100% Lifetime Risk Of Colorectal Cancer

Screenshot 2024-05-08 at 7.48.00 PM

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Untitled design - 2024-03-28T172702.605

Biodexa&#39;s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Redington 2_29

PowerShares Dynamic Financial Sector Portfolio

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Comments

Biodexa Pharmaceuticals

Notizie

Ultime notizie per Biodexa Pharmaceuticals (NASDAQ:BDRX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO